Figure 4
From: RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker
Kaplan–Meier survival curves of 68 neuroblastoma patients: correlation of pretherapeutic serum RASSF1A methylation status with overall survival (A) and relapse-free survival (B). M, methylated: patients with serum methylation of RASSF1A. U, unmethylated: patients without serum methylation of RASSF1A. The 5-year overall survival was more than 90% in patients without methylation, whereas lower than 50% in patients with methylation (P<0.001).
